Jasper Therapeutics Launches Buyback of Outstanding Stock Warrants
Jasper Therapeutics is offering $0.324 per warrant to repurchase all outstanding warrants from its 2025 public offering, aiming to limit shareholder dilution.
Jasper Therapeutics, Inc. (Nasdaq: JSPR), a clinical-stage biotechnology company based in Redwood City, California, announced Wednesday it has launched a formal offer to purchase all outstanding warrants tied to shares of its common stock, according to a company statement.
The warrants in question were originally issued during an underwritten public offering on September 18, 2025. Jasper is offering holders $0.324 in cash per warrant, with no interest accrued, and any warrants tendered under the offer will be retired and permanently cancelled.
Read more JLL Income Property Trust Secures $68.5M Indianapolis Industrial Loan →
The company cited dilution reduction as the primary driver of the move. By buying back the warrants before they can be exercised, Jasper aims to limit the total number of common shares that could enter the market, giving current shareholders and potential investors clearer visibility into the company's capital structure.
The announcement reflects a broader trend among small-cap biotechs using warrant repurchase programs to manage equity overhang — a concern that can weigh on stock valuations when large numbers of warrants remain outstanding and exercisable at below-market prices.
Continue reading at GlobeNewswire - Industry News on Financial Services.
